0001213900-24-061184.txt : 20240715 0001213900-24-061184.hdr.sgml : 20240715 20240715091612 ACCESSION NUMBER: 0001213900-24-061184 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240715 DATE AS OF CHANGE: 20240715 EFFECTIVENESS DATE: 20240715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NLS Pharmaceutics Ltd. CENTRAL INDEX KEY: 0001783036 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-518686 FILM NUMBER: 241115984 BUSINESS ADDRESS: STREET 1: THE CIRCLE 6 STREET 2: 8058 CITY: ZURICH STATE: V8 ZIP: CH-6370 BUSINESS PHONE: 41-41-618-80-00 MAIL ADDRESS: STREET 1: THE CIRCLE 6 STREET 2: 8058 CITY: ZURICH STATE: V8 ZIP: CH-6370 D 1 primary_doc.xml X0708 D LIVE 0001783036 NLS Pharmaceutics Ltd. THE CIRCLE 6 ZURICH V8 SWITZERLAND CH-8058 +41.44.512.2150 SWITZERLAND None None Other Limited Company true Alexander Zwyer The Circle 6 Zurich V8 SWITZERLAND CH-8058 Executive Officer Director Chief Executive Officer Ronald Hafner The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Eric Konofal The Circle 6 Zurich V8 SWITZERLAND CH-8058 Executive Officer Chief Scientific Officer and Interim Chief Medical Officer Elena Thyen-Pighin The Circle 6 Zurich V8 SWITZERLAND CH-8058 Executive Officer Chief Financial Officer Gian-Marco Rinaldi The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Audrey Greenberg The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Claudio L.A. Basseti The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Florence Allouche Aknin The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Pharmaceuticals Decline to Disclose 06b false 2024-06-28 false true true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Ave 3rd Floor New York NY NEW YORK 10022 NY NEW YORK false 786660 786660 0 Represents total gross proceeds received by the company in connection with a concurrent registered directoffering of common shares and concurrent private placement of warrants to purchase common shares. false 2 62933 0 H.C. Wainwright & Co., LLC ("Wainwright") acted as the placement agent in connection with the offering. Wainwright received an aggregate fee equal to 8.0% of the gross proceeds raised in the offering and warrants to purchase up to 229,443 common shares. 0 false NLS Pharmaceutics Ltd. /s/ Alexander Zwyer Alexander Zwyer Chief Executive Officer 2024-07-12